The AZI2 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the AZI2 gene in the A-549 human lung adenocarcinoma epithelial cell line. This loss-of-function model enables investigation of innate immune signaling by disrupting the expression of the NAP1/TBKBP1 adaptor protein.
The parental A-549 cell line is a well-established model derived from a 58-year-old Caucasian male with lung adenocarcinoma. These cells harbor a KRAS G12S mutation while retaining wild-type p53, and exhibit epithelial morphology. They are widely employed to study alveolar epithelial biology, oncogenic transformation, and drug responses. Importantly, A-549 cells support infection by various respiratory viruses, making them a relevant platform for investigating innate antiviral mechanisms.
AZI2 (NAP1/TBKBP1) functions as a scaffold adaptor downstream of pattern recognition receptors including RIG-I, MDA5, TLR3, and TLR4. Upon stimulation, AZI2 associates with TANK, NAP1, and TRAF3 to recruit and activate the kinases TBK1 and IKK??. These kinases subsequently phosphorylate transcription factors IRF3 and IRF7, as well as NF-??B, which translocate to the nucleus to induce type I interferons (e.g., IFN-??) and interferon-stimulated genes (ISGs). Consequently, AZI2 is a critical node in the MAVS- and TRIF-dependent branches of innate immunity that coordinate antiviral and inflammatory responses.
In the KRAS-mutant A-549 lung adenocarcinoma background, AZI2 knockout provides a valuable system to explore the intersection of innate immunity and cancer biology. Impaired antiviral signaling may enhance susceptibility to oncolytic viruses or alter responses to immune checkpoint inhibitors. Furthermore, because NF-??B and interferon pathways influence tumor cell proliferation, survival, and cytokine secretion, loss of AZI2 can modify the tumor microenvironment and drug sensitivity. This polyclonal knockout model thus enables detailed mechanistic studies of how innate adaptor proteins impact lung cancer pathophysiology.
Typical experiments with these knockout cells include phospho-signaling analysis via western blotting for TBK1, IRF3, and NF-??B; RT-qPCR for IFN-?? and ISG mRNA; and luciferase reporter assays for interferon or NF-??B activation. Co-immunoprecipitation can map AZI2 interactions with TBK1, IKK??, or TANK, while flow cytometry and immunofluorescence visualize downstream effects. Viral infection challenges with respiratory pathogens assess functional antiviral competence. Additionally, drug sensitivity screens can identify compounds that exploit innate immune defects in KRAS-mutant cancer. For technical support or custom applications, please contact Ascent Research.
